PharmTech Drug Digest 11.20
News|Articles|September 27, 2013

Catalent Applied Drug Delivery Institute Appoints New Advisory Board Member

Author(s)Melanie Sena

Catalent Applied Drug Delivery Institute appoints Claus-Michael Lehr to advisory board.

The Catalent Applied Drug Delivery Institute, an institute formed by Catalent Pharma Solutions, to promote collaboration between industry and academia, provide applied drug-delivery education and training, and advanced drug delivery, has appointed Claus-Michael Lehr, Head of the Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University, Germany and Co-founder and Head of the Department “Drug Delivery” of the Helmholtz Institute for Pharmaceutical Research Saarlandto the institute’s advisory board.

Professor Lehr has t more than 15 years researching ways to overcome biological barriers to effective drug delivery and the development and formulation of appropriate carriers to transport active pharmaceutical and biopharmaceutical molecules to desired targets. He has co-authored many publications on the development of sophisticated in-vitro models that represent the epithelial cells and tissues concerned in transport, and the application of nanotechnology to improve in-vivo delivery to such therapeutic targets.

Source: Catalent


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.